These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 26216863

  • 1. Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA).
    Yeh TC, Kao LC, Tzeng NS, Kuo TB, Huang SY, Chang CC, Chang HA.
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan 04; 64():60-7. PubMed ID: 26216863
    [Abstract] [Full Text] [Related]

  • 2. Effects of depression and melatonergic antidepressant treatment alone and in combination with sedative-hypnotics on heart rate variability: Implications for cardiovascular risk.
    Chang CC, Tzeng NS, Yeh CB, Kuo TBJ, Huang SY, Chang HA.
    World J Biol Psychiatry; 2018 Aug 04; 19(5):368-378. PubMed ID: 28281386
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Changes in heart rate variability in first-episode drug-naïve adolescents with major depressive disorder: A 12-week prospective study.
    Park SW, Lee JH, Kim J, Suh S, Lee MS.
    J Affect Disord; 2018 Oct 01; 238():250-255. PubMed ID: 29890452
    [Abstract] [Full Text] [Related]

  • 7. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P, Shu L, Xu X, Wang CY, Lee MS, Liu CY, Hong JP, Ruschel S, Raskin J, Colman SA, Harrison GA.
    Psychiatry Clin Neurosci; 2007 Jun 01; 61(3):295-307. PubMed ID: 17472599
    [Abstract] [Full Text] [Related]

  • 8. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
    Shu L, Sulaiman AH, Huang YS, Fones Soon Leng C, Crutel VS, Kim YS.
    Asian J Psychiatr; 2014 Apr 01; 8():26-32. PubMed ID: 24655622
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treating each and every depressed patient.
    Kennedy SH.
    J Psychopharmacol; 2008 Sep 01; 22(7 Suppl):19-23. PubMed ID: 18753279
    [Abstract] [Full Text] [Related]

  • 13. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
    Lôo H, Hale A, D'haenen H.
    Int Clin Psychopharmacol; 2002 Sep 01; 17(5):239-47. PubMed ID: 12177586
    [Abstract] [Full Text] [Related]

  • 14. Hypomania soon after shifting from paroxetine to agomelatine in a middle-aged woman with depression.
    Tu KY, Lin PY.
    Clin Neuropharmacol; 2014 Sep 01; 37(3):82-3. PubMed ID: 24824663
    [Abstract] [Full Text] [Related]

  • 15. Clinical efficacy of agomelatine in depression: the evidence.
    den Boer JA, Bosker FJ, Meesters Y.
    Int Clin Psychopharmacol; 2006 Feb 01; 21 Suppl 1():S21-4. PubMed ID: 16436936
    [Abstract] [Full Text] [Related]

  • 16. Distinguishing bipolar II depression from unipolar major depressive disorder: Differences in heart rate variability.
    Chang HA, Chang CC, Kuo TB, Huang SY.
    World J Biol Psychiatry; 2015 Feb 01; 16(5):351-60. PubMed ID: 25800950
    [Abstract] [Full Text] [Related]

  • 17. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
    Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A.
    J Clin Psychiatry; 2010 May 01; 71(5):616-26. PubMed ID: 20361916
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
    Olié JP, Kasper S.
    Int J Neuropsychopharmacol; 2007 Oct 01; 10(5):661-73. PubMed ID: 17477888
    [Abstract] [Full Text] [Related]

  • 19. Heart rate variability as a biomarker of anxious depression response to antidepressant medication.
    Kircanski K, Williams LM, Gotlib IH.
    Depress Anxiety; 2019 Jan 01; 36(1):63-71. PubMed ID: 30311742
    [Abstract] [Full Text] [Related]

  • 20. Agomelatine: efficacy at each phase of antidepressant treatment.
    Kennedy SH.
    CNS Drugs; 2009 Jan 01; 23 Suppl 2():41-7. PubMed ID: 19708725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.